Advertisement
Global  

“News neutrality by unbiased coverage”
One News Page
> >

Genentech’s Investigational Personalized Medicine Entrectinib Shrank Tumors in People with NTRK Fusion-Positive Solid Tumors

Business Wire Sunday, 21 October 2018
Genentech’s Investigational Personalized Medicine Entrectinib Shrank Tumors in People with NTRK Fusion-Positive Solid TumorsSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from an integrated analysis of the pivotal Phase II STARTRK-2, Phase I STARTRK-1 and Phase I ALKA-372-001 trials that showed the investigational personalized medicine entrectinib shrank tumors (objective response rate; ORR) in more than half (57.4 percent) of people with neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive solid tumors. Objective
0
shares
ShareTweetSavePostSend
 

You Might Like


Tweets about this


Other recent news in Press Releases

Manufacturing INDONESIA 2018: Bringing Technologies to Drive Industry 4.0 for Successful EconomyOmaha Steaks Announces BLACK FRIDAY and Cyber Monday Specials in-Store and Online
AMERICAN National Bankshares Inc. Announces Fourth Quarter 2018 DividendNew Research Coverage Highlights Chuy's, Viveve Medical, ClearSign Combustion, WhiteHorse FINANCE, Crinetics Pharmaceuticals, and Boston Omaha — Consolidated Revenues, Company Growth, and Expectations for 2018
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2018 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Contact us  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest